Cargando…

Targeting PIN-1 Attenuates GCB DLBCL Cell Proliferation Through Inhibition of PI3K/AKT Signaling

INTRODUCTION: Diffuse large B cell lymphoma (DLBCL) is a highly heterogeneous type of non-Hodgkin lymphoma with many molecular subtypes that can be distinguished by gene expression profiling (GEP). However, the pathogenesis of DLBCL is still unclear. MATERIALS AND METHODS: The expression levels of t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Haijun, Zhang, Ping, Li, Junkuo, Gao, Yang, Zhao, Luyao, Li, Jia, Guo, Mei, Zhang, Jingfang, Li, Haimei, Wang, Fuqiang, Yuan, Yufen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457679/ https://www.ncbi.nlm.nih.gov/pubmed/32904547 http://dx.doi.org/10.2147/OTT.S247429

Ejemplares similares

Efficacy and safety of zanubrutinib plus R-CHOP in treatment of non-GCB DLBCL with extranodal involvement
por: Geng, Hongzhi, et al.
Publicado: (2023)

Primary Cutaneous DLBCL Non-GCB Type: Challenges of a Rare Case
por: Sica, Antonello, et al.
Publicado: (2020)

Prognostic value of expression of nuclear factor kappa-B/p65 in non-GCB DLBCL patients
por: Wang, Jing, et al.
Publicado: (2016)

GNA13 regulates BCL2 expression and the sensitivity of GCB-DLBCL cells to BCL2 inhibitors in a palmitoylation-dependent manner
por: Xia, Zhizhou, et al.
Publicado: (2021)

P1196: ORIENT STUDY: REGIMEN OF ORELABRUTINIB PLUS R-CHOP-LIKE FOR PATIENTS WITH NEWLY DIAGNOSED UNTREATED NON-GCB DLBCL
por: Qu, Chang-Ju, et al.
Publicado: (2023)

P1219: ZANUBRUTINIB, LENALIDOMIDE PLUS R-CHOP (ZR2-CHOP) AS THE FIRST-LINE TREATMENT FOR NON-GCB DIFFUSED LARGE B-CELL LYMPHOMA (DLBCL)
por: Zhu, H., et al.
Publicado: (2022)

P1185: ANTITUMOR ACTIVITY AND SAFETY OF ZANUBRUTINIB COMBINED WITH R-CHOP REGIMEN IN THE TREATMENT OF NEWLY DIAGNOSED NON-GCB DLBCL WITH EXTRANODAL INVOLVEMENT: A PROSPECTIVE PHASE II STUDY.
por: Li, C., et al.
Publicado: (2022)

P1190: EFFICACY AND SAFETY OF SELINEXOR COMBINING WITH R-CHOP IN THE TREATMENT OF NEWLY DIAGNOSED HIGH RISK (IPI 3-5) GCB SUBTYPE DLBCL PATIENTS: A MULTICENTER RETROSPECTIVE REAL-WORLD STUDY FROM CHINA.
por: Zhi-Ming, LI, et al.
Publicado: (2023)

Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker
por: Batlle-López, Ana, et al.
Publicado: (2016)

A super-SILAC based proteomics analysis of diffuse large B-cell lymphoma-NOS patient samples to identify new proteins that discriminate GCB and non-GCB lymphomas
por: van der Meeren, L. E., et al.
Publicado: (2019)

The Silencing of Pokemon Attenuates the Proliferation of Hepatocellular Carcinoma Cells In Vitro and In Vivo by Inhibiting the PI3K/Akt Pathway
por: Lin, Chan-Chan, et al.
Publicado: (2012)

Germinal Center B Cell-Like (GCB) and Activated B Cell-Like (ABC) Type of Diffuse Large B Cell Lymphoma (DLBCL): Analysis of Molecular Predictors, Signatures, Cell Cycle State and Patient Survival
por: Blenk, S., et al.
Publicado: (2007)

β-Arrestin-2 attenuates hepatic ischemia-reperfusion injury by activating PI3K/Akt signaling
por: Chen, Xiaolong, et al.
Publicado: (2020)

Ginsenoside Rg3 Attenuates Lipopolysaccharide-Induced Acute Lung Injury via MerTK-Dependent Activation of the PI3K/AKT/mTOR Pathway
por: Yang, Jing, et al.
Publicado: (2018)

Duvelisib attenuates bleomycin‐induced pulmonary fibrosis via inhibiting the PI3K/Akt/mTOR signalling pathway
por: Li, Xiaohe, et al.
Publicado: (2023)

Loss of FAM60A attenuates cell proliferation in glioma via suppression of PI3K/Akt/mTOR signaling pathways
por: Liu, Xiaocen, et al.
Publicado: (2021)

FOXP1-GINS1 axis promotes DLBCL proliferation and directs doxorubicin resistance
por: Chen, Zhenfa, et al.
Publicado: (2023)

DUXAP10 inhibition attenuates the proliferation and metastasis of hepatocellular carcinoma cells by regulation of the Wnt/β-catenin and PI3K/Akt signaling pathways
por: Han, Kun, et al.
Publicado: (2019)

Arctiin attenuates iron overload-induced osteoporosis by regulating the PI3K/Akt pathway
por: Li, Miao, et al.
Publicado: (2023)

Adiponectin Attenuates Lipopolysaccharide-induced Apoptosis by Regulating the Cx43/PI3K/AKT Pathway
por: Liu, Luqian, et al.
Publicado: (2021)

Fenofibrate Attenuated Glucose-Induced Mesangial Cells Proliferation and Extracellular Matrix Synthesis via PI3K/AKT and ERK1/2
por: Zeng, Rui, et al.
Publicado: (2013)

Comparison of the algorithms classifying the ABC and GCB subtypes in diffuse large B-cell lymphoma
por: Boltežar, Lučka, et al.
Publicado: (2018)

CXCR4 can induce PI3Kδ inhibitor resistance in ABC DLBCL
por: Kim, Joo Hyun, et al.
Publicado: (2018)

PIN1 Protects Hair Cells and Auditory HEI-OC1 Cells against Senescence by Inhibiting the PI3K/Akt/mTOR Pathway
por: Zhang, Yanzhuo, et al.
Publicado: (2021)

Cucurbitacin E inhibits osteosarcoma cells proliferation and invasion through attenuation of PI3K/AKT/mTOR signalling pathway
por: Wang, Ying, et al.
Publicado: (2016)

Down-regulation of cylindromatosis protein phosphorylation by BTK inhibitor promotes apoptosis of non-GCB-diffuse large B-cell lymphoma
por: Xu, Xin, et al.
Publicado: (2021)

Downregulation of NCL attenuates tumor formation and growth in HeLa cells by targeting the PI3K/AKT pathway
por: Ying, Jun, et al.
Publicado: (2022)

Recombinant Human Brain Natriuretic Peptide Attenuates Myocardial Ischemia-Reperfusion Injury by Inhibiting CD4(+) T Cell Proliferation via PI3K/AKT/mTOR Pathway Activation
por: Li, Kun-Peng, et al.
Publicado: (2020)

The Immunology of DLBCL
por: Takahara, Taishi, et al.
Publicado: (2023)

CpG-ODN Attenuates Pathological Cardiac Hypertrophy and Heart Failure by Activation of PI3Kα-Akt Signaling
por: Yang, Liang, et al.
Publicado: (2013)

Shikonin promotes autophagy in BXPC-3 human pancreatic cancer cells through the PI3K/Akt signaling pathway
por: SHI, SHUQING, et al.
Publicado: (2014)

P1174: PI3K INHIBITOR LINPERLISIB COMBINED WITH GEMCITABINE AND OXALIPATIN (GEMOX) IN RELAPSED AND/OR REFRACTORY DLBCL: ANALYSIS BASED ON TUMOR BIOLOGY
por: Zhi-Ming, LI, et al.
Publicado: (2023)

Periostin promotes the proliferation and metastasis of osteosarcoma by increasing cell survival and activates the PI3K/Akt pathway
por: Xu, Chaojian, et al.
Publicado: (2022)

TRIM3 attenuates apoptosis in Parkinson's disease via activating PI3K/AKT signal pathway
por: Dong, Wenwen, et al.
Publicado: (2020)

Based on network pharmacology, gastrodin attenuates hypertension-induced vascular smooth muscle cell proliferation and PI3K/AKT pathway activation
por: Shen, Aling, et al.
Publicado: (2023)

Resveratrol attenuates high glucose-induced nucleus pulposus cell apoptosis and senescence through activating the ROS-mediated PI3K/Akt pathway
por: Wang, Wenping, et al.
Publicado: (2018)

RBP4 regulates trophoblastic cell proliferation and invasion via the PI3K/AKT signaling pathway
por: Li, Hongxia, et al.
Publicado: (2018)

SIK2 attenuates proliferation and survival of breast cancer cells with simultaneous perturbation of MAPK and PI3K/Akt pathways
por: Zohrap, Neslihan, et al.
Publicado: (2018)

Metformin Attenuates UVA-Induced Skin Photoaging by Suppressing Mitophagy and the PI3K/AKT/mTOR Pathway
por: Chen, Qiuyan, et al.
Publicado: (2022)

Knockdown of Ski decreases osteosarcoma cell proliferation and migration by suppressing the PI3K/Akt signaling pathway
por: Zhao, Xin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_kougu98a80eu07bpuiqh5ln5uv